Newest One 5x4ml
Important Notice
Medical device regulated by the European Medical Device Regulation (MDR), intended exclusively for authorized healthcare professionals. By purchasing, the customer declares to be authorized for their professional activity; false information may entail legal responsibilities.
Newest® One is the large-volume presentation of the Newest line from Mastelli S.r.l.: 5 vials of 4 ml with PN-HPT® polynucleotides, non-cross-linked hyaluronic acid and mannitol. It reproduces the principle of Newest — biostimulation and hydration in a single solution — in a diluted formulation designed to treat extensive areas of the face and body.
- Actives PN-HPT® + non-cross-linked HA
- With mannitol
- Contents 5 vials × 4 ml (20 ml)
- Plane intradermal
- Protocol 3–4 sessions / 14–21 days
Composition and technology
- Declared composition: water, PN-HPT® polynucleotides, sodium hyaluronate, mannitol, sodium chloride, sodium phosphate and disodium phosphate.
- Diluted formulation: this is the low-concentration version of the Newest line, adjusted for the treatment of large surfaces. Mastelli does not publish a single, verifiable mg/ml figure for this reference; the exact concentrations should be consulted on the pack data sheet. To know precisely the PN-HPT® and hyaluronic acid delivered per session, the documented reference in the line is Newest in a 2 ml syringe (PN-HPT® 10 mg/ml + HA 10 mg/ml).
- Origin of the polynucleotides: trout gonads from aquaculture intended for human consumption, subjected to Mastelli's proprietary high-purification process, which removes proteins and contaminants of potential allergenic character.
- Mechanism of action: the polynucleotides stimulate the fibroblast to synthesise glycosaminoglycans, collagen and elastin and bind water in the extracellular matrix; the non-cross-linked hyaluronic acid provides hydration without generating volume. Mannitol is included as an antioxidant excipient.
Position within the Mastelli range
| Plinest | PN-HPT® 20 mg/ml (40 mg / 2 ml) — 1 syringe of 2 ml. High concentration: face, neck, décolletage and dorsum of the hands |
|---|---|
| Plinest Fast | PN-HPT® 7.5 mg/ml (15 mg / 2 ml) — 1 syringe of 2 ml. Low concentration for thin or sensitive skin and for skin preparation |
| Plinest Eye | PN-HPT® 7.5 mg/ml — 1 syringe of 2 ml. Periocular indication |
| Plinest Hair | PN-HPT® 7.5 mg/ml — 1 syringe of 2 ml. Indication for the scalp, eyebrows and beard |
| Plinest One | PN-HPT® 2 mg/ml (8 mg per 4 ml vial) — 5 vials of 4 ml. Diluted formulation for large surfaces and the body |
| Newest | PN-HPT® 10 mg/ml + non-cross-linked HA 10 mg/ml + mannitol — 1 syringe of 2 ml |
| Newest One | PN-HPT® + non-cross-linked HA + mannitol in diluted formulation — 5 vials of 4 ml, body and large surfaces |
| Ialest | Non-cross-linked HA 20 mg/ml (2 %), without polynucleotides — 1 syringe of 2 ml |
Newest One and Plinest One share the same format (5 vials of 4 ml) and large-surface indication; the difference is that Newest One incorporates non-cross-linked hyaluronic acid and mannitol, and Plinest One does not. Plenhyage XL Strong, which is marketed alongside this range, does not belong to the Mastelli family: it is a brand of Bioformula S.r.l.
Indications and treatment areas
- Dry, dehydrated or dull skin over extensive surfaces
- Loss of firmness and elasticity
- Stretch marks and scars
- Revitalisation after procedures and in skin with irregular texture
Areas: face, neck, décolletage, dorsum of the hands, arms, abdomen, buttocks and inner thighs.
Technique and treatment protocol
- Injection plane: intradermal.
- Technique: microdeposits or micropapules, linear retrograde or fanning, according to the area.
- Needle: the consensus literature on PN-HPT® recommends 30 to 32G needles of 13 mm.
- Vial presentation: the product is drawn into a syringe before application; the pack does not include pre-filled syringes.
- Protocol: 1 session every 14 or 21 days up to a total of 3 sessions; 4 sessions in advanced signs of ageing.
Technical data
| Manufacturer | Mastelli S.r.l., Sanremo (Italy) |
|---|---|
| Active substances | PN-HPT® polynucleotides + non-cross-linked hyaluronic acid (sodium hyaluronate) |
| Other components | Mannitol, sodium chloride, sodium phosphate, disodium phosphate, water |
| Origin of the polynucleotides | Trout gonads from aquaculture, highly purified |
| Presentation | 5 vials of 4.0 ml (20 ml in total) |
| Route of administration | Injectable — intradermal |
| Classification | CE-marked medical device |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: between 2 °C and 25 °C, protected from direct sunlight and heat sources. Do not freeze.
- Do not use after the expiry date shown on the pack.
- Sterile single-use product: one vial per session. Do not reuse, re-sterilise or keep the remaining contents of an opened vial.
- The pack contains: 5 vials of 4 ml, instructions for use and traceability labels.
Contraindications and warnings
Known hypersensitivity to any of the components; pregnancy and breastfeeding; active autoimmune diseases; active skin infection or inflammation in the treatment area; coagulation disorders or anticoagulant therapy; ongoing oncological treatment; patients under 18 years of age.
As this is a product of fish origin, assess any history of fish allergy before application.
Always consult the instructions for use included in the pack before application. The binding contraindications are those set out in the official documentation accompanying the product.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the documentation of Mastelli S.r.l. and on the published clinical literature on PN-HPT®. This data sheet does not replace the instructions for use accompanying the product.